HFpEF involves heterogenous etiologies and comorbidities. Diagnosis relies on imaging, natriuretic peptides, and guideline-recommended algorithms. Sodium-glucose cotransporter-2 inhibitors show strong evidence, while beta-blockers are discouraged unless comorbidities warrant use.

Fluid retention in heart failure remains challenging; recent trials highlight high-dose loop diuretics' benefits over low-dose, yet guidelines lag. Improved research is crucial for advancing diuretic strategies and outcomes.

This study suggests that vitamin C deficiency may contribute to pulmonary hypertension (PH) and right ventricular enlargement, with improvement in mean pulmonary artery pressure (mPAP) following vitamin C supplementation.

A 37-year-old woman developed acute heart failure from macrophage activation syndrome following lupus onset post-gynecological procedure. The paper reviews macrophage roles across organs, diagnostic criteria, and cardiac involvement.

Acute heart failure affects millions globally, with high readmission and death rates. Rapid, full-dose treatment can induce remissions, highlighting the urgent need for collaborative efforts to improve implementation and outcomes.

This framework outlines essential heart failure competencies for diverse healthcare professionals, emphasizing multidisciplinary collaboration to address complex patient needs, supporting future professionals in delivering comprehensive heart failure care.

This review explores mitochondrial dysfunction and inflammation in heart failure, focusing on mitochondrial dynamics, ultrastructure changes, and therapeutic targets to improve cardiac function and energy metabolism.

Empagliflozin benefits cardiovascular outcomes and renal function in heart failure patients with diabetes, regardless of baseline insulin use, and reduces the need for sustained insulin initiation in non-insulin users.

The PREVENT equations assess 10- and 30-year cardiovascular disease risk, incorporating CKM syndrome predictors, kidney function, and social determinants of health to enhance primary prevention strategies for diverse populations.

The 2022 ACC/AHA/HFSA and 2021 ESC guidelines for heart failure align on key recommendations but differ due to timing; this review highlights differences to support evidence-based clinical decision-making.

The study identified five multimorbidity groups in acute heart failure patients, highlighting distinct clinical outcomes and treatment responses, emphasizing the importance of comorbidity patterns in managing these patients.

New therapies, including SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs, enhance cardiovascular and renal outcomes in high-risk patients with diabetes and heart failure, significantly improving patient management.

The Convoy-Pal intervention demonstrated feasibility and potential benefits for heart failure patients and their caregivers, highlighting the need for digital tools that effectively integrate both parties in palliative care.

Catheter ablation significantly improves survival, reduces heart failure re-hospitalization, enhances left ventricular function, and quality of life in atrial fibrillation patients with heart failure compared to medical therapy.

This study found no significant difference in stroke and thromboembolism risk between atrial fibrillation patients with preserved or reduced ejection fraction, suggesting ejection fraction shouldn't factor into stroke risk assessments.

A study compared heart failure patients in the Moravian Midlands Registry with Paradigm-HF trial participants, revealing younger age, higher BMI, lower ejection fraction, and more device therapies in the MMR cohort.

Dietary sodium restriction in chronic heart failure patients may worsen prognosis, increasing composite mortality and hospitalization risk without significantly affecting overall mortality or heart failure admissions.